KMnO oxidizes pseudoephedrine hydrochloride to produce methcathinone, a Schedule I drug in the United States. Consequently, the DEA has restricted its use and sale by classifying it as a List I controlled precursor. Potassium permanganate is listed as a Table I precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.